分子生物学
IVD分子诊断
细胞培养与分析
蛋白研究
细胞因子
重组蛋白
抗体
高通量测序建库
病原检测UCF系列
生物医药
工具酶
抑制剂激活剂与常用试剂
仪器
耗材

CRMP2 inhibits metastasis formation by impairing ILF3-dependent stabilization of CXCL10 mRNA in breast cancer

Lin Binyan, Luo Mei, Zhou Yanqing, Liu Xin, Zhu Qin, Weng Zebin, Li Lei, Cao Tao, Sun Jing, Yang Dawei, Liu E-Hu

Journal:Cell Death & Disease

IF:12.2

DOI:10.1038/s41419-026-08515-5

PMID:41735286

Published:2026-02-24

research field:转化医学癌症生物学分子肿瘤学RNA生物学细胞信号转导

Abstract

Tumor-derived elements contribute to the formation of the pre-metastatic niche (PMN) and facilitate cancer metastasis, but much less is known about the key molecular mechanisms. Here, we demonstrate that collapsin response mediator protein 2 (CRMP2), a critical regulator of the cytoskeleton, is associated with metastasis in breast cancer. CRMP2 overexpression inhibits both lung metastasis and PMN formation in breast cancer. Mechanistically, CRMP2 overexpression leads to downregulation of CXCL10. We also found that the correlation between CRMP2 and CXCL10 is mediated by interleukin enhancer-binding factor 3 (ILF3). The D-hydantoinases (D-HYD) fragment of CRMP2 specifically interacts with the second double-stranded RNA binding motif (dsRBM2) of ILF3. Overexpressed CRMP2 reduces the expression of ILF3 in proteasome-dependent degradation via Lys 48-linked polyubiquitination at Lys 257 , Lys 332 and Lys 413 . In addition, ILF3 directly binds to CXCL10 mRNA, thereby increasing CXCL10 mRNA stability. Finally, we found that psoralen interacts with CRMP2 and suppresses the development of lung metastases in breast cancer. In conclusion, our findings uncover a critical CRMP2-related mechanism behind breast tumor metastasis, and the CRMP2-ILF3-CXCL10 axis may provide a potential therapeutic strategy for controlling breast cancer metastasis.

本文使用的Yeasen产品

购物车
客服
转染试用